Feature | September 11, 2012

Maquet Study Results May Invalidate Industry Standard for Treating Cardiogenic Shock

The Impella percutaneous left ventricular assist devices (pLVAD) is an emerging option for partial or total circulatory support. In several randomized, controlled trials, pLVAD therapy demonstrated a better hemodynamic profile compared to IABP, although this did not translate into improved 30-day survival with use of pLVAD therapy.

September 11, 2012 — Primary results from an ongoing trial by Maquet Cardiovascular using intra-aortic balloon pumps (IABP) as an adjuvant treatment for myocardial infarction (MI) complicated by cardiogenic shock have shown no difference in patient survival when compared to standard care alone. Although IABP proved to be safe, the study’s results provide little evidence that use of IABP therapy is associated with hemodynamic improvement, a trait that has been considered critical to its clinical application for more than 40 years. The IABP-SHOCK II trial, conducted between 37 centers in Germany with 600 randomized patients over the course of three years, represents the largest trial ever performed in cardiogenic shock.

Since their introduction in 1968, IABPs have been the most widely used support device in the treatment of MI complicated by cardiogenic shock, with several million people having received treatment using IABP therapy to date. IABP provides temporary, mechanical circulatory support in an attempt to create a more favorable balance of oxygen supply and demand. Through systolic unloading and diastolic augmentation, the cardiac output, ejection fraction (EF) and rate of coronary perfusion are increased, while left ventricular wall stress, systemic resistance to left EF, and pulmonary capillary wedge pressure are decreased. Use of IABP therapy for cardiogenic shock patients during the ‘80s and ‘90s was limited to around 20 percent of cases; however, there has been a temporal trend towards increased use over the years, with rates currently estimated at 25 to 40 percent.

Until now, only a few registry studies and clinical trials have shown that IABP therapy can improve blood pressure and the perfusion of the coronary arteries. Based on this limited data, international guidelines recommend the use of IABP therapy in patients with cardiogenic shock, although, as evident in the frequency of use, many cardiologists are still not entirely convinced of its efficacy. It was for this reason that the IABP-SHOCK II trial was initiated, aiming to provide evidence that use of IABP therapy, currently a Class I recommendation, would reduce the 30-day mortality rate in patients compared to standard care. Besides failing to reduce rates of mortality, use of IABP showed no improvement in blood pressure, no reduction in treatment time in the intensive care unit, no decrease in the duration or dose of drugs prescribed and no improvement in organ perfusion. Several subgroups were additionally evaluated and also showed no clear benefit in using IABP.

While IABP therapy is currently the workhorse circulatory support device used by cardiovascular specialists, GlobalData believes that the Class I recommendation will now be strongly challenged. Previous studies have explored the use of IABP and even reported positive results; however, no trials have had the breadth, statistical significance and randomization of the SHOCK II trial. With this most recent announcement of SHOCK II’s primary results, it is expected that cardiologists will further question continued use of IABP therapy, although six-month and 12-month mortality data must be assessed before any definitive conclusions can be made.

Treatment strategies for patients with cardiogenic shock have come to a key turning point, and results of this most recent IABP trial have left a therapeutic void to fill. Percutaneous left ventricular assist devices (pLVAD) represent an emerging option for partial or total circulatory support and more than one study has compared the safety and efficacy of these devices with IABP. In several randomized, controlled trials, pLVAD therapy demonstrated a better hemodynamic profile compared to IABP, although this did not translate into improved 30-day survival with use of pLVAD therapy. The most common pLVADs studied currently are the TandemHeart developed by CardiacAssist and the Abiomed Impella LP2.5. As pLVAD technology continues to improve, further studies will be required to determine its effectiveness. Muscular counterpulsation exemplifies a noninvasive alternative to IABP therapy and has shown some promise, although more clinical research must be conducted before conclusions can be made.

Besides Maquet, who recently acquired Datascope’s cardiovascular portfolio, other companies with IABP products include Arrow and Abiomed. The results of the SHOCK II study provide a huge opportunity to develop novel and innovative strategies to treat cardiogenic shock, and room for another company to seize market control for this indication. GlobalData expects IABP therapy will be targeted to a more specific target population in future studies where it is deemed most effective, and that pLVAD therapy may undergo further development to improve survival rates.

For more information: www.globaldata.com/ExpertsInsightDetails.aspx?PRID=347&companyID=jpr

Related Content

heart failure, after first heart attack, cancer risk, JACC study
News | Cardiac Diagnostics| July 21, 2016
People who develop heart failure after their first heart attack have a greater risk of developing cancer when compared...
mitral valve surgery outcomes, twisting of the heart, echocardiography, NICSMR, JACC Basic to Translational Science
News | Heart Valve Technology| July 20, 2016
A novel study has found a simple pre-operative echocardiographic measurement of the amount of torsion of the heart...
TITAN II Trial, Carillon Mitral Contour System, Cardiac Dimensions, Open Heart journal, functional mitral regurgitation, FMR
News | Annuloplasty Rings| July 20, 2016
New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment...
Mitralign, Trialign system, tricuspid regurgitation. SCOUT U.S. study, phase 1 enrollment
News | Heart Valve Technology| July 19, 2016
Mitralign Inc. announced last week it has completed subject enrollment in the SCOUT early feasibility study in the...
sudden cardiac arrest, out-of-hospital, comatose patients, University of Arizona study, wake up
News | Sudden Cardiac Arrest| July 13, 2016
Physicians may be drawing conclusions too soon about survival outcomes of patients who suffered a cardiac arrest...
radial access, inserting stents, JACC Cardiovascular Interventions study
News | Radial Access| July 13, 2016
A new study in JACC: Cardiovascular Interventions supports access through the wrist, or radial access, as the default...
University of Guelph study, heart failure risk, gender, aging
News | Heart Failure| July 08, 2016
University of Guelph researchers have uncovered a possible clue as to why women have lower rates of heart failure than...
Abbott, FIRM-guided rotor ablation, atrial fibrillation, clinical studies, Cardiostim 2016
News | EP Mapping and Imaging Systems| July 07, 2016
July 7, 2016 — Abbott recently announced positive results from three clinical studies investigating the benefits asso
AtriCure, FROST cryoanalgesia study, William Beaumont Hospital Michigan, cryoICE system
News | Left Atrial Appendage (LAA) Occluders| July 07, 2016
AtriCure Inc. announced the first patient has been enrolled in the FROST study at William Beaumont Hospital, Dearborn,...
SynCardia acquired, Versa Capital Management, chapter 11
News | Business| July 07, 2016
SynCardia Systems Inc. announced that it has entered into an asset purchase agreement (“APA”) with an affiliate of...
Overlay Init